NHS Greater Glasgow & Clyde Area Drug and Therapeutics Committee
Greater Glasgow and Clyde Medicines
Medicines Update Oncology

New WOSCAN protocols (May 2015)

The following West of Scotland Cancer Network (WOSCAN) protocols are now available on the WOSCAN intranet site (NHS network access required):

  • Lenalidomide in combination with dexamethasone, for the treatment of multiple myeloma in adult patients who have received at least one prior therapy 
    • For protocol click here.  
    • The GGC Formulary entry has been updated. Click here.
    • For relevant SMC advice click here.
  • Pomalidomide in combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
    • For protocol click here.  Please note: new MHRA advice re pomalidomide has now been published (20th May 2015).  The protocol has been updated to reflect this advice. 
    • The GGC Formulary entry has been updated. Click here.
    • For relevant SMC advice click here.
  • Cetuximab for the treatment of patients with epidermal growth factor receptor expressing, RAS wild-type metastatic colorectal cancer.  Please note the SMC have accepted this for the following restricted indication "for use in patients with RAS wild-type metastatic colorectal cancer, in combination with irinotecan or oxaliplatin-based chemotherapy, in patients who have not previously received chemotherapy for their metastatic disease (first-line treatment)".   
    • For Cetuximab in combination with Modified De Gramont plus Irinotecan protocol click here.  This replaces the previous version.  An updated protocol for Cetuximab in combination with Modified de Gramont plus Oxaliplatin has still to be issued. Please note: the cetuximab is administered in a 2 weekly schedule in both these protocols.  This 'off-label' dose schedule has been endorsed by the RPASG and is supported by clinical evidence base.
    • The GGC Formulary entry has been updated.  Click here.
    • For relevant SMC advice click here.
  • Everolimus for the treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with vascular endothelial growth factor (VEGF) targeted therapy.
    • For protocol click here.
    • The GGC Formulary entry has been updated.  Click here.
    • For relevant SMC advice click here.